Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer

University of Ulm

Status and phase

Unknown

Phase 2

Conditions

Pancreas Neoplasms

Treatments

Drug: Docetaxel

Drug: Oxaliplatin

Study type

Interventional

Funder types

Other

Identifiers

NCT00690300

I1-GOA-1

EudraCT 2005-004236-40

Details and patient eligibility

About

The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy.

Full description

For years Fluorouracil was the established treatment for pancreatic cancer with median survival times up to 8 months. Since 1997 Gemcitabine is also a standard therapy with in comparison to Fluorouracil a significant better clinical benefit.

But after progression of the disease under a palliative first-line therapy there is no established second line therapy for pancreatic cancer.

So the purpose of this study is to test the combination of Oxaliplatin and Docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy to get a reasonable second line concept.

Enrollment

44 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Dated and signed informed concent
Histologically or cytologically proven metastatic or locally advanced adenocarcinoma of the exocrine pancreas (stadium UICC III/IV)
Presence of at least one measurable (according to RECIST criteria) marker lesion (primary tumor or metastasis) outside of an area that was previously subjected to radiation therapy
Failure of a palliative first line therapy of a metastatic or locally advanced adenocarcinoma of the exocrine pancreas due to: Progress within 3 months after a first-line therapy Discontinuation of a first-line therapy due to toxicity
Age >= 18 years
Karnofsky index > 60%
Expected live span > 12 weeks
Sufficient bone marrow reserve: Granulocytes >= 1.5 x 109/L and Platelets >= 100 x 109/L and Hemoglobin >= 9 g/L
Serum Bilirubin < 2 x upper normal limit or 2.5 x upper normal limit in case of hepatic metastasis (biliary drainage allowed)
AST/ALT < 2.5 x upper normal limit

Exclusion criteria

Every other cancer or secondary cancer besides the basal cell carcinoma of the skin or the carcinoma in situ of the cervix uteri. Inclusion of patients with other types of cancer that were successfully treated and that did not relapse within the last 5 years is possible
Pregnancy or lactation
Patients able to reproduce that do not adhere to strict contraception
Presence of brain metastasis
Severe, uncontrolled infection
Preexisting peripheral neuropathy > grade I
Preexisting severe illnesses such as unstable coronary artery disease or uncontrolled cardiac arrhythmia
Justified disbelief in the compliance of the patient
Parallel participation in another clinical trial